CN114891740B - Culture method and application of NK cells with high proliferation capacity and high cytotoxicity - Google Patents
Culture method and application of NK cells with high proliferation capacity and high cytotoxicity Download PDFInfo
- Publication number
- CN114891740B CN114891740B CN202210302864.3A CN202210302864A CN114891740B CN 114891740 B CN114891740 B CN 114891740B CN 202210302864 A CN202210302864 A CN 202210302864A CN 114891740 B CN114891740 B CN 114891740B
- Authority
- CN
- China
- Prior art keywords
- concentration
- cells
- cytokine
- cell culture
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000000822 natural killer cell Anatomy 0.000 title claims abstract description 94
- 230000003013 cytotoxicity Effects 0.000 title claims abstract description 25
- 231100000135 cytotoxicity Toxicity 0.000 title claims abstract description 25
- 230000035755 proliferation Effects 0.000 title claims abstract description 15
- 238000012136 culture method Methods 0.000 title abstract description 7
- 238000004113 cell culture Methods 0.000 claims abstract description 40
- 210000004027 cell Anatomy 0.000 claims abstract description 22
- 108010002350 Interleukin-2 Proteins 0.000 claims abstract description 20
- 238000012258 culturing Methods 0.000 claims abstract description 17
- 210000005087 mononuclear cell Anatomy 0.000 claims abstract description 16
- 239000011248 coating agent Substances 0.000 claims abstract description 12
- 238000000576 coating method Methods 0.000 claims abstract description 12
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims abstract description 9
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims abstract description 8
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims abstract description 8
- 239000006143 cell culture medium Substances 0.000 claims abstract description 7
- 210000005259 peripheral blood Anatomy 0.000 claims abstract description 7
- 239000011886 peripheral blood Substances 0.000 claims abstract description 7
- 238000000926 separation method Methods 0.000 claims abstract description 7
- 238000011534 incubation Methods 0.000 claims abstract description 4
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 26
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 26
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 26
- 239000000243 solution Substances 0.000 claims description 26
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 24
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 24
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 claims description 21
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 claims description 21
- 102000000588 Interleukin-2 Human genes 0.000 claims description 19
- 230000004913 activation Effects 0.000 claims description 18
- 102000013462 Interleukin-12 Human genes 0.000 claims description 14
- 108010065805 Interleukin-12 Proteins 0.000 claims description 14
- BQRXMLXVGQMIBO-UHFFFAOYSA-N 1,1-bis(sulfanyl)ethanol Chemical compound CC(O)(S)S BQRXMLXVGQMIBO-UHFFFAOYSA-N 0.000 claims description 13
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims description 13
- 102000003812 Interleukin-15 Human genes 0.000 claims description 13
- 108090000172 Interleukin-15 Proteins 0.000 claims description 13
- 102000003810 Interleukin-18 Human genes 0.000 claims description 13
- 108090000171 Interleukin-18 Proteins 0.000 claims description 13
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 13
- 229960000905 indomethacin Drugs 0.000 claims description 13
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 claims description 12
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 12
- 229930182816 L-glutamine Natural products 0.000 claims description 12
- 229930003268 Vitamin C Natural products 0.000 claims description 12
- 229930003427 Vitamin E Natural products 0.000 claims description 12
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 claims description 12
- 239000005516 coenzyme A Substances 0.000 claims description 12
- 229940093530 coenzyme a Drugs 0.000 claims description 12
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 claims description 12
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 12
- 235000019154 vitamin C Nutrition 0.000 claims description 12
- 239000011718 vitamin C Substances 0.000 claims description 12
- 235000019165 vitamin E Nutrition 0.000 claims description 12
- 229940046009 vitamin E Drugs 0.000 claims description 12
- 239000011709 vitamin E Substances 0.000 claims description 12
- 239000001963 growth medium Substances 0.000 claims description 10
- 210000004698 lymphocyte Anatomy 0.000 claims description 10
- 230000003213 activating effect Effects 0.000 claims description 7
- 239000007853 buffer solution Substances 0.000 claims description 3
- 231100000433 cytotoxic Toxicity 0.000 claims description 2
- 230000001472 cytotoxic effect Effects 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000003321 amplification Effects 0.000 abstract description 9
- 238000003199 nucleic acid amplification method Methods 0.000 abstract description 9
- 238000002360 preparation method Methods 0.000 abstract description 2
- 230000001502 supplementing effect Effects 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 22
- 239000002609 medium Substances 0.000 description 12
- 230000010261 cell growth Effects 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 230000002147 killing effect Effects 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 108700012411 TNFSF10 Proteins 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 3
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 3
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 102000009058 Death Domain Receptors Human genes 0.000 description 2
- 108010049207 Death Domain Receptors Proteins 0.000 description 2
- 101150089023 FASLG gene Proteins 0.000 description 2
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000004560 Interleukin-12 Receptors Human genes 0.000 description 2
- 108010017515 Interleukin-12 Receptors Proteins 0.000 description 2
- 101710097160 Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 description 2
- 230000005809 anti-tumor immunity Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000005909 tumor killing Effects 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102100024452 DNA-directed RNA polymerase III subunit RPC1 Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 101000689002 Homo sapiens DNA-directed RNA polymerase III subunit RPC1 Proteins 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- 102000000763 Survivin Human genes 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 210000004395 cytoplasmic granule Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Substances O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 230000026762 natural killer cell apoptotic process Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/44—Thiols, e.g. mercaptoethanol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2312—Interleukin-12 (IL-12)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2318—Interleukin-18 (IL-18)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/33—Insulin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/53—CD2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The application relates to the technical field of cell culture, and in particular discloses a culture method of NK cells with high proliferation capacity and high cytotoxicity and application thereof, comprising the following steps: s1, coating an anti-human CD16 monoclonal antibody with the concentration of 0.1-2.0 mg/mL in a cell culture flask, wherein the coating condition is 25 ℃, and the incubation time is 1-5 h; s2, taking a cell culture bottle subjected to coating treatment, adding an NK cell culture medium, and then adding mononuclear cells obtained by centrifugal separation from peripheral blood into the cell culture bottle, and adjusting the cell density to be 1X 106/mL-2X 106/mL; s3, continuously culturing the cell culture flask in a incubator with CO2 with the concentration of 2% at 37 ℃ for 9-15 days, and supplementing IL-2 with the concentration of 2-100 mug/mL every 3 days. The NK cells with high purity, high amplification efficiency and strong cytotoxicity can be obtained by adopting the preparation method of the application.
Description
Technical Field
The application relates to the technical field of cell culture, in particular to a culture method of NK cells with high proliferation capacity and high cytotoxicity and application thereof.
Background
NK cells, also called natural killer cells (natural killer cell), are a third class of lymphocytes other than T, B cells, a cell subset with unique functions, are one of lymphocytes in human immune cells, are a key subset of innate immune cells, are considered to be one of the main effector cells of the body for controlling the occurrence, development and metastasis of tumors, and are also the first natural defense line of the body for resisting tumors and infections.
The main mechanisms of NK cell anti-tumor immunity include: 1) Releasing cytoplasmic granules comprising perforin and granzyme to cause apoptosis of target cells, thereby clearing mutant tumor cells; 2) Death receptors mediate target apoptosis, NK cells express at least 3 TNF superfamily death ligands: fas ligand (Fas ligand, fasL), TNF and TNF-related apoptosis-inducing ligand (TNF related apoptosis inducing ligand, TRAIL) kill tumor cells by binding to their corresponding death receptors on their surfaces; 3) Cytokine mediated killing such as INF-gamma, TNF, granulocyte-macrophage colony stimulating factor, IL-5, IL-10, IL-13, etc.; 4) Antibody-dependent cell-mediated cytotoxicity (ADCC) is mediated primarily through fcγriii (CD 16) with low affinity at its membrane surface.
NK cells play an important role in both innate and adaptive immunity and are considered as important effector cells for tumor immunotherapy. NK cells are rare subpopulations of lymphocytes, accounting for only about 10% -20% of peripheral blood lymphocytes. NK cell content in peripheral blood of normal human body can not meet the clinical treatment requirement. Therefore, obtaining NK cells with high purity, high amplification efficiency and strong cytotoxicity has become a research hotspot.
Disclosure of Invention
In order to obtain NK cells with high purity, high amplification efficiency and strong cytotoxicity, the application provides a culture method of NK cells with high proliferation capacity and high cytotoxicity and application thereof.
In a first aspect, the present application provides a method for culturing NK cells with high proliferation capacity and high cytotoxicity, which adopts the following technical scheme:
a method for culturing NK cells with high proliferation capacity and high cytotoxicity, comprising the steps of:
s1, coating an anti-human CD16 monoclonal antibody with the concentration of 0.1-2.0 mg/mL in a cell culture flask, wherein the coating condition is 25 ℃, and the incubation time is 1-5 h;
s2, taking a cell culture bottle subjected to coating treatment, adding an NK cell culture medium, and then adding mononuclear cells obtained by centrifugal separation from peripheral blood into the cell culture bottle to adjust the cell density to be 1 multiplied by 10 6 /mL~2×10 6 /mL; the NK cell culture medium comprises a basic culture solution and an activating culture solution, wherein the adding amount of the activating culture solution is 3-5% of that of the basic culture solution; the activation culture solution comprises the following components in concentration: 1.2 to 1.5g/L of human serum albumin, 1.5 to 2.0g/L of human serum albumin, 120 to 160mg/L of vitamin C, 220 to 240mg/L of vitamin E, 120 to 150mg/L of coenzyme A, 0.5 to 5mg/L of recombinant human insulin, 280 to 330mg/L of L-glutamine, 420 to 530ug/mL of dimercaptoethanol, 20 to 30ug/mL of indomethacin, and 0.1 to 10 mu g/mL of Na + 50-100 ng/mL of monoclonal antibody CD2, 50-100 ng/mL of NKp46 antibody, 0.01-0.06 KE/mL of OK432 and 2-100 mug/mL of cytokine IL-2;
s3, placing the cell culture flask at 37 ℃ and CO with the concentration of 2% 2 The incubator is continuously cultured for 9 to 15 days, and IL-2 with the concentration of 2 to 100 mug/mL is added every 3 days.
By adopting the method to culture NK cells, NK cells with high purity, high amplification efficiency and strong cytotoxicity can be obtained. The reason is that the anti-human CD16 monoclonal antibody is selected to be coated in a cell culture flask, and the anti-human CD16 monoclonal antibody is combined with CD16 molecules in NK cells, so that a CD16 co-stimulation signal path is activated, and the activation and proliferation of the ANK cells can be promoted. The human serum albumin and the human serum albumin in the NK cell culture medium can provide basic culture components for the culture of NK cells; vitamin C and dimercaptoethanol can prevent oxidation of cells, increase toughness of cell wall, and Na + In the process of cell growth, the ion maintains the balance of the osmotic pressure inside and outside the cell, and can prevent the cell wall from cracking so as to promote the cell growth; vitamin E is a bioactive substance for cell growth, and can regulate and control during cell growth and metabolismThe preparation is carried out; the coenzyme A metabolism pathway can induce oxidative phosphorylation and enhance the anti-tumor effect of NK cells; recombinant human insulin can promote NK cell self-regulation and enhance cytotoxicity; l-glutamine is an encoded amino acid in protein synthesis, and can provide nutrients for the culture of NK cells; indomethacin can play an anti-inflammatory and anti-toxic role, has strong capability of inducing cytotoxicity (ADCC), and can inhibit the expression of Survivin factors in tumor cells, thereby effectively assisting in improving the killing activity of NK cells; monoclonal antibody CD2 and multifunctional antibody targeting NKp46 can activate anti-tumor immunity of NK cells; OK-432 can enhance the cytotoxicity of NK cells, promote secretion of IFN-r, IL-2, TNF-alpha and the like, and regulate the anti-tumor immune response of organisms; in the application, monoclonal antibodies CD2 and NKp46 and OK-432 are taken as a biological effector and added into a culture medium at the initial stage of cell culture, so that NK cells can be activated; in addition, the IL-2 can promote the growth of NK precursor cells and NK mature cells, increase the expression level of cytolytic enzymes secreted by NK cells and enhance NK cytotoxicity; the monoclonal antibody CD2 and NKp46 antibody and OK-432 and IL-2 are simultaneously present in a culture medium at the initial stage of cell culture, so that the expression rate of NK cells can be effectively improved, the amplification factor of the NK cells is greatly improved, and the in-vitro tumor killing activity is enhanced.
Preferably, the activation culture solution comprises the following components in each concentration: 1.3g/L human serum albumin, 1.8g/L human serum albumin, 130-140 mg/L vitamin C, 230-235 mg/L vitamin E, 130-140 mg/L coenzyme A, 3mg/L recombinant human insulin, 320 mg/L-glutamine, 450-480 ug/mL dimercaptoethanol, 26ug/mL indomethacin, 5 ug/mL Na + 60-70 ng/mL of monoclonal antibody CD2, 60-70 ng/mL of NKp46 antibody, 0.06KE/mL of OK432 and 2-50 mug/mL of cytokine IL-2.
Preferably, the activation culture solution comprises the following components in each concentration: 1.3g/L human serum albumin, 1.8g/L human serum albumin, 135mg/L vitamin C, 230mg/L vitamin E, 135mg/L coenzyme A, 3mg/L recombinant human insulin, 320 mg/L-glutamine, 460ug/mL dimercaptoethanol, 26ug/mL indomethacin, 5 ug/mL Na + Monoclonal antibody of 65ng/mLCD2, 65ng/mL NKp46 antibody, 0.06KE/mL OK432, 50 μg/mL cytokine IL-2.
By adopting the technical scheme, the combined factors with the concentrations are adopted in the activating culture solution, so that the expression rate of NK cells can be effectively improved, the amplification factor and cytotoxicity of the NK cells are greatly improved, and the in-vitro tumor killing activity is effectively enhanced.
Preferably, in the step S2, before the mononuclear cells are added into a cell culture flask, the mononuclear cells are pretreated for 10 to 15 hours with a culture solution consisting of the cytokine IL-12 with the concentration of 15 to 20ng/mL, the cytokine IL-15 with the concentration of 1 to 10ng/mL and the cytokine IL-18 with the concentration of 30 to 50ng/mL, then washed for 2 to 3 times by using PBS buffer solution, and then placed into the cell culture flask for culture.
By adopting the technical scheme, IL-12 achieves the effects of inhibiting tumor angiogenesis and mediating tumor apoptosis through tumor necrosis factor-related apoptosis-inducing ligand (tumor necrosis factor related apoptosis inducing ligand, TRAIL) and apoptosis factor ligand (fas ligand, fasL) by promoting NK cells to release interferon gamma (IFN-gamma) and tumor necrosis factor alpha (tumor necrosis factor alpha, TNF-alpha); IL-18 can enhance the effect of IL-12 by up-regulating the expression of NK cell surface IL-12receptor (IL-12R); IL-15 can sustain NK cell differentiation and expansion, and resist IL-2 mediated NK cell apoptosis.
Preferably, in the step S2, before the mononuclear cells are added into a cell culture flask, the mononuclear cells are pretreated for 13 hours with a culture solution composed of cytokine IL-12 with a concentration of 15ng/mL, cytokine IL-15 with a concentration of 5ng/mL and cytokine IL-18 with a concentration of 50ng/mL, then washed for 2 times by using PBS buffer, and then placed into the cell culture flask for culturing.
By adopting the technical scheme, the pretreatment is carried out before the NK cell culture by adopting a mode of combining the cytokines IL-12, IL-15 and IL-18, so that the NK cell can be efficiently amplified and the killing activity of the NK cell can be obviously activated.
Preferably, the basal medium is selected from Corning KBM 581 lymphocyte serum-free medium.
By adopting the technical scheme, the basic culture solution is rich in nutrition and meets the requirement of NK cell culture.
In a second aspect, the present application provides NK cells prepared by the culture method of NK cells having high proliferation potency and high cytotoxicity.
In a third aspect, the present application provides the use of high proliferative capacity and high cytotoxic NK cells in medicine for the treatment of tumors, infections or diseases of the immune system.
In summary, the application has the following beneficial effects:
1. by adopting the method to culture NK cells, NK cells with high purity, high amplification efficiency and strong cytotoxicity can be obtained.
2. The pretreatment is carried out before the NK cell culture by adopting a mode of combining the cytokines IL-12, IL-15 and IL-18, so that the NK cells can be efficiently amplified and the killing activity of the NK cells can be obviously activated.
Drawings
FIG. 1 is a bar graph showing NK cell expansion for different days in the method provided in examples and comparative examples of the present application.
Detailed Description
The application is described in further detail below with reference to the drawings and examples.
The instruments, materials, reagents, etc. used in the present application are commercially available unless otherwise specified.
Examples
Example 1
A method for culturing NK cells with high proliferation capacity and high cytotoxicity, comprising the steps of:
s1, coating an anti-human CD16 monoclonal antibody with the concentration of 0.1mg/mL in a cell culture flask, wherein the coating condition is 25 ℃, and the incubation time is 1h;
collecting human peripheral blood, transferring the collected peripheral blood into a 50mL centrifuge tube, centrifuging at 20 ℃ for 2000rmp for 10min, and collecting plasma for later use; separating and collecting peripheral blood mononuclear cells by using lymphocyte separating medium (corning), and cleaning the collected mononuclear cells with PBS for three times and counting for later use;
wherein, the method for separating and collecting peripheral blood mononuclear cells by using lymphocyte separation liquid comprises the following steps: 1. the blood sample after plasma aspiration was prepared according to 1:1, adding PBS according to the proportion, and uniformly mixing; 2. slowly adding the diluted blood sample on the lymphocyte separation liquid level, wherein the ratio of the diluted blood sample to the lymphocyte separation liquid is 1:1, a step of; 3. centrifuging at 2000rpm for 15min, and slowly increasing and decreasing at 20deg.C. 4. After centrifugation, mononuclear cell layer cells were aspirated.
S2, taking a cell culture bottle subjected to coating treatment, adding an NK cell culture medium, and then adding mononuclear cells obtained by centrifugal separation from peripheral blood into the cell culture bottle to adjust the cell density to be 1 multiplied by 10 6 /mL; the NK cell culture medium comprises a basic culture medium and an activating culture medium, wherein the adding amount of the activating culture medium is 4% of that of the basic culture medium, and the basic culture medium is selected from Corning KBM 581 lymphocyte serum-free culture medium; the activation culture solution comprises the following components in concentration: 1.2g/L human serum albumin, 1.5g/L human serum albumin, 120mg/L vitamin C, 220mg/L vitamin E, 120mg/L coenzyme A, 0.5mg/L recombinant human insulin, 280 mg/L-glutamine, 420ug/mL dimercaptoethanol, 20ug/mL indomethacin, 0.1 ug/mL Na + 50ng/mL of monoclonal antibody CD2, 50ng/mL of NKp46 antibody, 0.01KE/mL of OK432, 2 μg/mL of cytokine IL-2.
S3, placing the cell culture flask at 37 ℃ and CO with the concentration of 2% 2 Is continuously cultured for 14 days, and IL-2 with the concentration of 2 mug/mL is supplemented every 3 days.
S4, collecting cells, washing for 3 times by using PBS, and performing cell quality inspection, so that a large number of amplified NK cells with high purity, high proliferation capacity and high cytotoxicity are obtained after the cells are qualified, and are used for tumor cell treatment or cryopreservation.
Example 2
Example 2 differs from example 1 in that the activation medium comprises the following components in the respective concentrations: 1.3g/L human serum albumin, 1.8g/L human serum albumin, 130mg/L vitamin C,230mg/L vitamin E, 130mg/L coenzyme A, 3mg/L recombinant human insulin, 320 mg/L-glutamine, 450ug/mL dimercaptoethanol, 26ug/mL indomethacin, 5 ug/mL Na + 60ng/mL of monoclonal antibody CD2, 60ng/mL of NKp46 antibody, 0.06KE/mL of OK432, 50 μg/mL of cytokine IL-2.
Example 3
Example 3 differs from example 1 in that the activation medium comprises the following components in the respective concentrations: 1.3g/L human serum albumin, 1.8g/L human serum albumin, 135mg/L vitamin C, 230mg/L vitamin E, 135mg/L coenzyme A, 3mg/L recombinant human insulin, 320 mg/L-glutamine, 460ug/mL dimercaptoethanol, 26ug/mL indomethacin, 5 ug/mL Na + 65ng/mL of monoclonal antibody CD2, 65ng/mL of NKp46 antibody, 0.06KE/mL of OK432, 50 μg/mL of cytokine IL-2.
Example 4
Example 4 differs from example 1 in that the activation medium comprises the following components in the respective concentrations: 1.3g/L human serum albumin, 1.8g/L human serum albumin, 135mg/L vitamin C, 230mg/L vitamin E, 135mg/L coenzyme A, 3mg/L recombinant human insulin, 320 mg/L-glutamine, 460ug/mL dimercaptoethanol, 26ug/mL indomethacin, 5 ug/mL Na + 65ng/mL of monoclonal antibody CD2, 100ng/mL of NKp46 antibody, 0.06KE/mL of OK432, 50 μg/mL of cytokine IL-2.
Example 5
Example 5 differs from example 1 in that the activation medium comprises the following components in the respective concentrations: 1.3g/L human serum albumin, 1.8g/L human serum albumin, 140mg/L vitamin C, 235mg/L vitamin E, 140mg/L coenzyme A, 3mg/L recombinant human insulin, 320 mg/L-glutamine, 480ug/mL dimercaptoethanol, 26ug/mL indomethacin, 5 ug/mL Na + 70ng/mL of monoclonal antibody CD2, 70ng/mL of NKp46 antibody, 0.06KE/mL of OK432, 50 μg/mL of cytokine IL-2.
Example 6
Example 6 differs from example 1 in that the activation medium comprises the following components in the respective concentrations: 1.5g/L human serum albumin, 2.0g/L human serumAlbumin, vitamin C160 mg/L, vitamin E240 mg/L, coenzyme A150 mg/L, recombinant human insulin 5mg/L, L-glutamine 330mg/L, dimercaptoethanol 530ug/mL, indomethacin 30ug/mL, na 10 μg/mL + 100ng/mL of monoclonal antibody CD2, 100ng/mL of NKp46 antibody, 0.06KE/mL of OK432, 100 μg/mL of cytokine IL-2.
Example 7
Example 7 differs from example 3 in that in step S2, the mononuclear cells were pretreated with a culture solution composed of cytokine IL-12 at a concentration of 15ng/mL, cytokine IL-15 at a concentration of 1g/mL and cytokine IL-18 at a concentration of 30ng/mL for 10 hours before being added to the cell culture flask, washed with PBS buffer for 2 times, and then placed in the cell culture flask for culturing.
Example 8
Example 8 differs from example 3 in that in step S2, the mononuclear cells were pretreated with a culture medium comprising cytokine IL-12 at a concentration of 18ng/mL, cytokine IL-15 at a concentration of 5ng/mL and cytokine IL-18 at a concentration of 40ng/mL for 13 hours before being added to the cell culture flask, washed 2 times with PBS buffer, and then placed in the cell culture flask for culturing.
Example 9
Example 9 differs from example 3 in that in step S2, the mononuclear cells were pretreated with a medium composed of cytokine IL-12 at a concentration of 15ng/mL, cytokine IL-15 at a concentration of 5ng/mL and cytokine IL-18 at a concentration of 50ng/mL for 13 hours before being added to the cell culture flask, washed 2 times with PBS buffer, and then placed in the cell culture flask for culturing.
Example 10
Example 10 differs from example 3 in that in step S2, the mononuclear cells were pretreated with a medium comprising cytokine IL-12 at a concentration of 20ng/mL, cytokine IL-15 at a concentration of 10ng/mL and cytokine IL-18 at a concentration of 50ng/mL for 15 hours before being added to the cell culture flask, washed 3 times with PBS buffer, and then placed in the cell culture flask for culturing.
Comparative example
Comparative example 1
Comparative example 1 differs from example 1 in that in step S2, monoclonal antibody CD2 was not added to the activation medium.
Comparative example 2
Comparative example 2 differs from example 1 in that no targeted NKp46 antibody was added to the activation medium in step S2.
Comparative example 3
Comparative example 3 differs from example 1 in that in step S2, the targeting OK-432 was not added to the activation broth.
Comparative example 4
Comparative example 4 was different from example 1 in that in step S2, the concentration of monoclonal antibody CD2 added to the activation medium was 10ng/mL and the concentration of NKp46 antibody was 10ng/mL.
Comparative example 5
Comparative example 5 was different from example 1 in that in step S2, the concentration of monoclonal antibody CD2 added to the activation medium was 150ng/mL and the concentration of NKp46 antibody was 150ng/mL.
Performance test
1. NK cell expansion fold detection
Cultured cells were taken from examples 1 to 10 and comparative examples 1 to 5 on days 0, 7 and 14, respectively, counted after staining with trypan blue, and the total number of cells on the day of counting was divided by the number of cells before culturing (i.e., day 0), the number being the fold of expansion of the cells, and the results are shown in Table 1.
Table 1 comparison of amplification factors of examples and comparative examples
As can be seen from Table 1, the NK cell expansion factors of examples 1 to 10 of the present application are higher than those of comparative examples 1 to 5, wherein the NK cell numbers of the culture of example 9 reached 4000 to 8000 times after 7 days and the NK cell numbers of the culture of comparative examples 1 to 5 reached about 5000 times after 14 days.
It can be seen from the combination of examples 3 and 4 that NK cells can be effectively expanded when the concentration ratio of monoclonal antibody CD2 and NKp46 antibodies is 1:1.
As can be seen from the combination of example 1 and comparative examples 1-3, the monoclonal antibodies CD2 and NKp46 and OK-432 in the present application are added to the culture medium as a bioeffective agent at the initial stage of cell culture, and can activate NK cells, thereby greatly increasing the expansion factor of NK cells. It can be seen from the combination of example 1 and comparative examples 4 to 5 that the addition of monoclonal antibodies CD2 and NKp46 at a final concentration less than or greater than the final concentration defined in the present application affects the expansion of NK cells.
It can be seen from the combination of examples 3 and 7-10 that pretreatment of NK cells prior to culture by using a combination of cytokine IL-12, cytokine IL-15 and cytokine IL-18 can efficiently amplify NK cells. The NK cells in the example 9 have obvious expansion condition (burrs are arranged around the colony to generate and gradually increase) from the 7 th day of culture, the NK cell colony is smaller at the 14 th day, and the NK cells are rapidly increased after being dispersed, so that a large amount of expansion is realized, the cells are dispersed, and the activity is good.
2. NK cell purity assay
NK cells cultured for 14 days in example 3, example 9 and comparative example 1 were taken for flow assay to count the purity of NK cells. The detection result showed that the NK cells obtained in example 3 had a purity of 90.8% after 14 days of culture. The NK cells obtained in example 9 were cultured for 14 days and the purity of NK cells was 95.2%. The NK cells obtained in comparative example 1 were cultured for 14 days, and the purity of NK cells was 82.5%.
3. NK cell killing detection the tumor cells were subject to K562 tumor cells, and the NK cells obtained in inventive example 3, example 9 and comparative 1 were used to detect the killing activity against tumor cells. Killing experiments were performed with K562 as target cells, with effective target ratios of 20:1, 10:1, 5:1, and 1:1, respectively, and the results are shown in Table 2.
TABLE 2 killing Activity of NK cells obtained in example 9 and comparative example 1 against K562 tumor cells
It can be seen from Table 2 that pretreatment of NK cells prior to culturing by combination of cytokines IL-12, IL-15 and IL-18 can efficiently amplify NK cells and remarkably activate NK cell killing activity.
In conclusion, the NK cells are cultured by adopting the culture method provided by the application, so that the NK cells with high purity, high amplification efficiency and strong cytotoxicity can be obtained.
It is to be understood that the above embodiments are merely illustrative of the application of the principles of the present application, but not in limitation thereof. Various modifications and improvements may be made by those skilled in the art without departing from the spirit and substance of the application, and are also considered to be within the scope of the application.
Claims (5)
1. A method for culturing NK cells with high proliferation capacity and high cytotoxicity, comprising the steps of:
s1, coating an anti-human CD16 monoclonal antibody with the concentration of 0.1-2.0 mg/mL in a cell culture flask, wherein the coating condition is 25 ℃, and the incubation time is 1-5 h;
s2, taking a cell culture bottle subjected to coating treatment and adding an NK cell culture medium, then pretreating mononuclear cells obtained by centrifugal separation from peripheral blood for 10-15 hours by using a culture solution consisting of cytokine IL12 with the concentration of 15-20 ng/mL, cytokine IL15 with the concentration of 1-10 ng/mL and cytokine IL18 with the concentration of 30-50 ng/mL, then washing for 2-3 times by using PBS buffer solution, and then placing the culture solution into the cell culture bottle for culturing, adding the culture solution into the cell culture bottle, and regulating the cell density to be 1 multiplied by 10 6 /mL~2×10 6 /mL; wherein NK cell cultureThe culture medium comprises basic culture solution and activating culture solution, and the adding amount of the activating culture solution is 3-5% of that of the basic culture solution; the activation culture solution comprises the following components in concentration: 1.2-1.5 g/L human serum albumin, 1.5-2.0 g/L human serum albumin, 120-160 mg/L vitamin C, 220-240 mg/L vitamin E, 120-150 mg/L coenzyme A, 0.5-5 mg/L recombinant human insulin, 280-330 mg/L-glutamine, 420-530 ug/mL dimercaptoethanol, 20-30 ug/mL indomethacin, 0.1-10 ug/mL Na + 50-100 ng/mL of monoclonal antibody CD2, 50-100 ng/mL of NKp46 antibody, 0.01-0.06 KE/mL of OK432 and 2-100 mug/mL of cytokine IL2;
s3, placing the cell culture flask at 37 ℃ and CO with the concentration of 2% 2 The incubator is continuously cultured for 9 to 15 days, and IL2 with the concentration of 2 to 100 mug/mL is added every 3 days.
2. The method for culturing high proliferation potency and high cytotoxicity NK cells according to claim 1, wherein: the activation culture solution comprises the following components in concentration: 1.3g/L human serum albumin, 1.8g/L human serum albumin, 130-140 mg/L vitamin C, 230-235 mg/L vitamin E, 130-140 mg/L coenzyme A, 3mg/L recombinant human insulin, 320 mg/L-glutamine, 450-480 ug/mL dimercaptoethanol, 26ug/mL indomethacin, 5 ug/mL Na + 60-70 ng/mL of monoclonal antibody CD2, 60-70 ng/mL of NKp46 antibody, 0.06KE/mL of OK432 and 2-50 mug/mL of cytokine IL2.
3. The method for culturing high proliferation potency and high cytotoxicity NK cells according to claim 2, wherein: the activation culture solution comprises the following components in concentration: 1.3g/L human serum albumin, 1.8g/L human serum albumin, 135mg/L vitamin C, 230mg/L vitamin E, 135mg/L coenzyme A, 3mg/L recombinant human insulin, 320 mg/L-glutamine, 460ug/mL dimercaptoethanol, 26ug/mL indomethacin, 5 ug/mL Na + 65ng/mL of monoclonal antibody CD2, 65ng/mL of NKp46 antibody, 0.06KE/mL of OK432, 50 μg/mL of cytokine IL2.
4. The method for culturing high proliferation potency and high cytotoxicity NK cells according to claim 3, wherein: in the step S2, before the mononuclear cells are added into a cell culture bottle, the mononuclear cells are pretreated for 13 hours by a culture solution consisting of the cytokine IL12 with the concentration of 15ng/mL, the cytokine IL15 with the concentration of 5ng/mL and the cytokine IL18 with the concentration of 50ng/mL, then washed for 2 times by a PBS buffer solution, and then placed into the cell culture bottle for culture.
5. A method of culturing high proliferative and highly cytotoxic NK cells according to any one of claims 1-3, wherein: the basal culture solution is selected from Corning KBM 581 lymphocyte serum-free culture solution.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210302864.3A CN114891740B (en) | 2022-03-25 | 2022-03-25 | Culture method and application of NK cells with high proliferation capacity and high cytotoxicity |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210302864.3A CN114891740B (en) | 2022-03-25 | 2022-03-25 | Culture method and application of NK cells with high proliferation capacity and high cytotoxicity |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114891740A CN114891740A (en) | 2022-08-12 |
CN114891740B true CN114891740B (en) | 2023-12-01 |
Family
ID=82715980
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210302864.3A Active CN114891740B (en) | 2022-03-25 | 2022-03-25 | Culture method and application of NK cells with high proliferation capacity and high cytotoxicity |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114891740B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117343902B (en) * | 2023-12-04 | 2024-03-08 | 赛奥斯博生物科技(北京)有限公司 | In-vitro amplification culture method for high-purity NK cells |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140035102A (en) * | 2012-09-13 | 2014-03-21 | (주)케이셀바이오 | A METHOD FOR EXPANDING NK CELLS FROM PERIPHERAL BLOOD BELOW 100ml |
CN103756963A (en) * | 2012-12-13 | 2014-04-30 | 上海柯莱逊生物技术有限公司 | Method used for in vitro proliferation of NK cells |
CN105219713A (en) * | 2015-11-20 | 2016-01-06 | 崔长友 | For high proliferation power, the High Fragmentation power NK cell of tumour adoptive immunity |
CN105238754A (en) * | 2015-11-20 | 2016-01-13 | 赵顺英 | Method for in vitro culture of high-proliferation and high-mortality NK cells |
KR20160076607A (en) * | 2014-12-23 | 2016-07-01 | 정용윤 | Activation and production of NK cell in the elderly |
CN106222140A (en) * | 2016-08-04 | 2016-12-14 | 英普乐孚生物技术(上海)有限公司 | A kind of NK cell non-serum culture medium and compound method thereof |
CN107326008A (en) * | 2017-08-09 | 2017-11-07 | 上海莱馥医疗科技有限公司 | A kind of method of high-purity amplifying natural killer cell efficient from peripheral blood |
CN109666640A (en) * | 2019-01-14 | 2019-04-23 | 武汉睿健医药科技有限公司 | The method of the external pure culture of natural killer cells |
WO2021101270A1 (en) * | 2019-11-20 | 2021-05-27 | 주식회사 지아이셀 | Composition for culturing natural killer cells and method for preparing natural killer cells by using same |
WO2022055892A1 (en) * | 2020-09-08 | 2022-03-17 | Cytoimmune Therapeutics, Inc. | Methods and compositions of infecting, activating, and expanding immune cells |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2612918T3 (en) * | 2013-07-10 | 2017-05-19 | Miltenyi Biotec Gmbh | Method to induce the proliferation of natural killer cells by mobile nanomatrices |
US20210137983A1 (en) * | 2019-11-08 | 2021-05-13 | Innovative Cellular Therapeutics Holdings, Ltd. | Nk cell expansion and uses thereof |
-
2022
- 2022-03-25 CN CN202210302864.3A patent/CN114891740B/en active Active
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140035102A (en) * | 2012-09-13 | 2014-03-21 | (주)케이셀바이오 | A METHOD FOR EXPANDING NK CELLS FROM PERIPHERAL BLOOD BELOW 100ml |
CN103756963A (en) * | 2012-12-13 | 2014-04-30 | 上海柯莱逊生物技术有限公司 | Method used for in vitro proliferation of NK cells |
KR20160076607A (en) * | 2014-12-23 | 2016-07-01 | 정용윤 | Activation and production of NK cell in the elderly |
CN105219713A (en) * | 2015-11-20 | 2016-01-06 | 崔长友 | For high proliferation power, the High Fragmentation power NK cell of tumour adoptive immunity |
CN105238754A (en) * | 2015-11-20 | 2016-01-13 | 赵顺英 | Method for in vitro culture of high-proliferation and high-mortality NK cells |
CN106222140A (en) * | 2016-08-04 | 2016-12-14 | 英普乐孚生物技术(上海)有限公司 | A kind of NK cell non-serum culture medium and compound method thereof |
CN107326008A (en) * | 2017-08-09 | 2017-11-07 | 上海莱馥医疗科技有限公司 | A kind of method of high-purity amplifying natural killer cell efficient from peripheral blood |
CN109666640A (en) * | 2019-01-14 | 2019-04-23 | 武汉睿健医药科技有限公司 | The method of the external pure culture of natural killer cells |
WO2021101270A1 (en) * | 2019-11-20 | 2021-05-27 | 주식회사 지아이셀 | Composition for culturing natural killer cells and method for preparing natural killer cells by using same |
WO2022055892A1 (en) * | 2020-09-08 | 2022-03-17 | Cytoimmune Therapeutics, Inc. | Methods and compositions of infecting, activating, and expanding immune cells |
Non-Patent Citations (3)
Title |
---|
IL-2和IL-15诱导扩增的脐带血NK细胞生物学特性研究;汪健;孙自敏;曹琳琳;李庆;;中国实验血液学杂志(03);12-18 * |
Implication of Interleukin-12/15/18 and Ruxolitinib in the Phenotype, Proliferation, and Polyfunctionality of Human Cytokine-Preactivated Natural Killer Cells;Terrén等;Front Immunol;第9卷(第1-15期);1-15 * |
NK细胞的选择性扩增;赵敬湘;王字玲;;细胞与分子免疫学杂志(02);75-78 * |
Also Published As
Publication number | Publication date |
---|---|
CN114891740A (en) | 2022-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mueller et al. | A Viscum album oligosaccharide activating human natural cytotoxicity is an interferon γ inducer | |
CN113151168B (en) | Human NK cell culture system and preparation method thereof | |
CN103923879B (en) | A kind of preparation method of NK cytokine mixture and application thereof | |
US20030068306A1 (en) | Medium | |
EP0317141A2 (en) | Method of purging residual tumor cells in vitro with lymphokine activated cytotoxic cells | |
CN115558641B (en) | High-purity effector immune cell population, culture method, reagent composition and application thereof | |
CN115651903B (en) | High-lethality immune cell population, and culture method, reagent composition and application thereof | |
CN113046313A (en) | Composition and kit for efficiently inducing and amplifying human peripheral blood killer immune cells and culture method of immune cells | |
CN114891740B (en) | Culture method and application of NK cells with high proliferation capacity and high cytotoxicity | |
CN115521914B (en) | In-vitro amplification system and method for human primary natural killer cells | |
CN113462646A (en) | Simple and effective method for induced amplification of iNKT cells and application | |
CN116333986A (en) | Culture method for exosome activated NK cells | |
CN110438077B (en) | Method for simultaneously culturing NK and gamma delta T cells | |
CN112391344A (en) | In-vitro amplification and culture method for non-coated NK cells | |
CN111117961B (en) | Tumor antigen loaded DC-CIK cell culture method | |
CN116240168A (en) | Preparation and application of NK cells | |
CN116445406A (en) | In-vitro simple culture system and culture method for NK cells derived from umbilical cord blood | |
CN115466726A (en) | High-efficiency gene transduction scheme of NK (natural killer) cells | |
JP2024502012A (en) | Method for preparing tumor-infiltrating lymphocytes | |
CN110607276A (en) | Serum-free culture method for efficiently amplifying cord blood NK cells | |
CN116490607A (en) | Tumor infiltrating lymphocyte culture medium and application thereof | |
Te Velde et al. | Monocyte mediated cytotoxic activity against melanoma | |
CN111235107A (en) | Additive and culture medium for immune cell culture and immune cell culture method | |
EP0348290A2 (en) | Activated killer monocytes : tumoricidal activity and method of monitoring same | |
CN115404215A (en) | Method for efficiently activating and amplifying NK immune cells in vitro |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |